alexa Should be or Not Use Haematopoietic Growth Factors in the Case of Druginduced Agranulocytosis | OMICS International
ISSN: 2155-9864
Journal of Blood Disorders & Transfusion
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Should be or Not Use Haematopoietic Growth Factors in the Case of Druginduced Agranulocytosis

Emmanuel Andrès*, Rachel Mourot, Olivier Keller and Adrian Purcarea

Department of Internal Medicine, B Clinic, University Hospital of Strasbourg, Strasbourg, 67000 Strasbourg, France

Corresponding Author:
Pr. E. Andres
Service de Médecine Interne, Clinique Médicale B
CHRU de Strasbourg, 1 Place de l’Hôpital
67000 Strasbourg Cedex, France
Tel: +33 (3) 88 11 50 66
Fax: +33 (3) 88 11 62 62
E-mail: [email protected]

Received Date: January 14, 2014; Accepted Date: January 23, 2014; Published Date: January 26, 2014

Citation: Andrès E, Mourot R, Keller O, Purcarea A (2014) Should be or Not Use Haematopoietic Growth Factors in the Case of Drug-induced Agranulocytosis. J Blood Disord Transfus 5:e108. doi:10.4172/2155-9864.1000e108

Copyright: © 2014 Andrès E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Blood Disorders & Transfusion

Keywords

Agranulocytosis; Neutropenia; Haematopoietic growth factors; G-CSF

Drug-induced agranulocytosis is characterized by a severe decrease of neutrophil count of at least <0.5×109/L, in association with the intake of drugs such as: anti-thyroid drugs, antibiotics, ticlopidine, sulfasalazine, and dipyrone [1]. Currently, the incidence of this idiosyncratic adverse effect is estimated to be between 2.4 and 15.4 cases per one million inhabitants. From a clinical perspective, druginduced agranulocytosis may simply be detected following a routine full blood count, or it may present with the onset of infection with varying degrees of severity, for example, ranging from fever with no clear focus, septicaemia and septic shock, to more localized infections mostly involving the ear nose and throat, the lungs and the skin [1,2].

In oldest studies, the mortality of drug-induced agranulocytosis due to complications resulting from infection ranged from 10% to 16% [2]. At present, this mortality is closer to 5% (between 2.5% and 10%), illustrating the progress that has been made in the recognition and therapeutic management of this condition [1]. Notify that drug-induced agranulocytosis can rapidly become a life threatening condition, hence the importance of optimal clinical management. To our opinion, this includes the use of haematopoietic growth factors such as Granulocyte Colony-Stimulating Factor (G-CSF), which are not yet, in developed countries, licenced for this condition [3].

To date, the efficacy and mainly the usefulness of haematopoietic growth factors in drug-induced agranulocytosis is still a matter of debate. A systematic meta-analysis by Andersohn et al. (n=492) found that since 1985 over two-thirds of reported cases were treated with these agents [2]. Most recent studies demonstrate a significant reduction in the duration of agranulocytosis following the use of these cytokines [2,3]. In our own experience, the administration of G-CSF, at a mean dose of 300 μg/day, is associated with a significant reduction in the duration of agranulocytosis, antibiotic use and length of hospital stay, particularly in patients with poor prognostic factors [4,5]. Only one single study showed a survival benefit when using neutrophil growth factors [6]. The most recent data did not find any significant difference in the mortality rate of patients treated or not treated with G-CSF or GM-CSF: 5% versus 6% in the study of Andersohn et al.; 8.9% versus 11.4% in the study of Ibanez et al. [2,7]. The prospective, randomized study carried out by Fukata et al. (the only one available to date), was also unable to draw any definitive conclusions regarding the use of neutrophil growth factors [8].

A critical review of the data available support the role of neutrophil growth factors in the presence of at least one of the poor prognostic factors [1,9,10]. In our experience, these factors includes: age over 65 years, neutrophil count at diagnosis of less than 0.1×109/L, development of severe intercurrent infection (septicaemia and septic shock) as well as pre-existing co-morbidities (in particular renal impairment, defined by a serum creatinine level >120 μmol/L) [10]. A neutrophil count of <0.1×109/L appears to be a particularly important prognostic factor [9,10].

To date, the true impact of the use of haematopoietic growth factors is still being questioned, but these molecules appear to indisputably decrease the duration of agranulocytosis, antibiotic course and length of hospital stay. Finally, it would be beneficial to conduct further public health studies (such as meta-analysis of reported data form the series of Berlin, Barcelona, Strasbourg…) in order to fully confirm the potential use of these agents.

Conflict of Interest

The authors have no conflicts of interest that are directly relevant of the content of this manuscript. Professor E. Andrès is recipient of a grant from the Laboratoires AMGEN, NOVARTIS, AVANTIS, GSK, PFIZER, FERRING and CHUGAI, but this sponsor had no part in the research or writing of the present manuscript. Professor E. Andrès is an active member of the various French national or international commissions or group, but the present manuscript represents individual opinion.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11619
  • [From(publication date):
    February-2014 - Dec 17, 2017]
  • Breakdown by view type
  • HTML page views : 7850
  • PDF downloads : 3769
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]com

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version